1. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice 
Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck-Lissbrant, Jan-Erik Damber, Anders Widmark, Camilla Thellenberg-Karlsson, Lars Budäus, Thomas Steuber, Till Eichenauer, Per Wollmer, Lars Edenbrandt, Elin Trägårdh, Anders Bjartell 
European Urology Focus 
Volume 2, Issue 5, Pages (December 2016)
DOI: /j.euf
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1 Flowchart showing distribution of the participating patients.
AA=abiraterone acetate; mCRPC=metastatic castration-resistant prostate cancer.
European Urology Focus 2016 2, DOI: ( /j.euf )
Copyright © 2016 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier curves showing patient-survival probability stratified by Bone Scan Index (BSI) change categories at follow-up. BSI changes from baseline to follow-up were evaluated among the 104 patients studied. Patients presenting BSI change values ≤0.30 (n=54) and BSI change values >0.30 (n=50) showed significantly different survival rates during the follow-up period (p<0.001).
BSI=Bone Scan Index.
European Urology Focus 2016 2, DOI: ( /j.euf )
Copyright © 2016 European Association of Urology Terms and Conditions

4. Fig. 3
(a) Baseline and (b) follow-up whole-body bone scans of a metastatic castration-resistant prostate cancer patient treated with abiraterone acetate. Hot spots, presented in red, represent the bone area affected by a tumour. The Bone Scan Index (BSI) change from baseline to follow-up suggests BSI progression in accordance with patient's significant BSI increase (BSI change >0.30).
AA=abiraterone acetate; BSI=Bone Scan Index.
European Urology Focus 2016 2, DOI: ( /j.euf )
Copyright © 2016 European Association of Urology Terms and Conditions